Stock Information
Stock Quote
Stock Chart
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Sign up to receive the latest information about Inozyme Pharma and its research and development programs.
You are now signing up to receive email updates and news from Inozyme Pharma. The emails you will receive are not intended to provide you with healthcare advice. Inozyme Pharma will not and does not provide healthcare advice. By registering for this email service, you understand that you are not disclosing any personal, private health information to Inozyme Pharma.
You must be 18 years of age or older to register. By registering to receive these emails, you certify that you are 18 years of age or older and are granting permission to receive general updates and news from Inozyme Pharma.
By providing your information, you agree to allow Inozyme Pharma and its agents to collect the name and email address provided and to be contacted by Inozyme Pharma and its agents using this information in the future. Furthermore, you are agreeing that Inozyme Pharma and its agents may contact you by email. Inozyme Pharma will not sell, rent, or otherwise distribute your name and email address provided.
Email Alerts
Print
SearchFooter
©2021 Inozyme Pharma.
All Rights Reserved.
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton that can be life-threatening and debilitating.
Close
Privacy/Cookie Policy & User Agreement
This site uses cookies as described in our Cookies Policy. To learn more about cookies, including how to disable them, view our Cookies Policy. By clicking the "Accept" or “Close” on this banner, or using our site, you consent to the use of Cookies, unless you disable them.
Accept